Company Encyclopedia
View More
name
Crinetics Pharmaceuticals
CRNX.US
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity.
4.514 T
CRNX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking51/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-44.42%E
    • Profit Margin-27563.32%E
    • Gross Margin-63161.54%E
  • Growth ScoreB
    • Revenue YoY47.74%A
    • Net Profit YoY-52.24%D
    • Total Assets YoY27.59%A
    • Net Assets YoY28.71%A
  • Cash ScoreB
    • Cash Flow Margin-0.36%D
    • OCF YoY47.74%A
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio10.36%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Crinetics Pharmaceuticals Chief Medical and Development Officer Dana Pizzuti Reports Disposal of Common Shares

    Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, reported the disposal of common shares of the company. This information was published via EDGAR by the U.S. Securities and Exchange Commission on December 3, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    CRNX
    +0.94%
    Reuters·
    US
    CRNX
    +0.94%

    Assessing Crinetics Pharmaceuticals Valuation After Stock Volatility and Pipeline Progress in 2025

    Crinetics Pharmaceuticals is assessed for its valuation amidst stock volatility and pipeline progress. Despite recent stock declines, long-term gains are significant. Analysts view the company as a potential leader in its niche, with a DCF analysis suggesting it's undervalued by 61%. The price-to-book ratio is in line with fundamentals, indicating a demanding but not excessive valuation. Investors are encouraged to consider narratives for a holistic understanding of its future potential.

    Simplywall·
    US
    CRNX
    +0.94%
    Simplywall·
    US
    CRNX
    +0.94%

    Crinetics Pharmaceuticals shares are trading higher after the company announced it does its first patient n the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2-positive neuroendocrine tumors and other SST2-expressing solid tumors.

    benzinga_article·
    US
    CRNX
    +0.94%
    benzinga_article·
    US
    CRNX
    +0.94%

    Crinetics Pharmaceuticals Doses First Patient in Phase 1/2 Trial of CRN09682 for Neuroendocrine Tumors

    Crinetics Pharmaceuticals has dosed the first patient in its Phase 1/2 trial of CRN09682 for treating SST2-positive neuroendocrine tumors. The BRAVESST2 trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, enrolling up to 150 participants. This trial marks a significant step in Crinetics' drug development efforts.

    Reuters·
    US
    CRNX
    +0.94%
    Reuters·
    US
    CRNX
    +0.94%

    Ensign Peak Advisors Inc Sells 199,245 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

    Ensign Peak Advisors Inc reduced its stake in Crinetics Pharmaceuticals by 38.7% in Q2, selling 199,245 shares. Other institutional investors adjusted their positions, with notable transactions by Decheng Capital LLC, Natixis Advisors LLC, Commerce Bank, PNC Financial Services Group Inc., and Vanguard Group Inc. Insiders sold 30,000 shares recently. Crinetics stock opened at $42.86, with a market cap of $4.07 billion. Analysts forecast growth, with price targets raised by Robert W. Baird, Goldman Sachs, and Oppenheimer.

    Market Beat·
    US
    CRNX
    +0.94%
    Market Beat·
    US
    CRNX
    +0.94%
    © 2025 Longbridge｜Disclaimer